FDA on Wednesday ((Oct. 30) said all formulations of Novo Nordisk’s semaglutide GLP-1 drugs Ozempic and Wegovy are no longer in shortage, but on the same day the agency revealed its inspection of Novo Nordisk’s largest facility for producing semaglutide drugs found manufacturing process issues that may allow microorganism contamination. The removal of drugs from the shortage list means they generally cannot be compounded unless for patient-specific reasons. Novo has asked FDA to shut down semaglutide compounders over allegations their...